Boehringer Ingelheim and Lupin have entered into a partnership to co-market Empagliflozin used for treatment of type 2 diabetes in India.
Under the co-marketing agreement, Lupin will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin’s specialty field force.
Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through their existing sales force and network.
This deal will help Lupin to enrich their anti-diabetic portfolio in Indian market. The Indian diabetes market is valued at Rs 9,003 crore, growing at 19.5 per cent as per IMS MAT July 2016.